Skip to main content

Advertisement

SpringerLink
Log in

Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Chemotherapy is administered only to patients with advanced cancers, typically to modest avail. Hence, the search for innovative approaches to treat cancer is growing rapidly. One such approach involves targeting molecular pathways identified as encouraging tumor growth and maintenance, particularly the type 1 insulin-like growth factor (IGF-1) and its receptor (IGF-1R) pathway that is important in conferring chemoresistance.

Materials and Methods

This study focuses on IGF-1R targeted therapy, which will enhance chemotherapy efficacy, through reviewing recent literature from PubMed and Medline databases.

Conclusion

This review examines data and strategies addressing an approach conquering chemoresistance through the combination of IGF-1R targeted therapy and chemotherapy in cancer patients, as well as the mechanisms by which IGF-1R acts as a target. This will impact on future research on treatment selection, thereby improving patient prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E (2008) Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 20:731–735

    CAS  PubMed  Google Scholar 

  • Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Therapeutics 315:971–979

    Article  CAS  Google Scholar 

  • Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H et al (2008) A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. ASCO Meet Abstr 26:3519

    Google Scholar 

  • Bohula EA, Playford MP, Macaulay VM (2003) Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 14:669–682

    Article  CAS  PubMed  Google Scholar 

  • Burfeind P, Chernicky C, Rininsland F, Ilan J, Ilan J (1996) Antisense RNA to the type 1 insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93:7263–7268

    Article  CAS  PubMed  Google Scholar 

  • Busund L, Ow K, Russell P, Crowe PJ, Yang J (2004) Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 444:142–148

    Article  CAS  PubMed  Google Scholar 

  • Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor 1 receptor. Cancer Res 65:3781–3787

    Article  CAS  PubMed  Google Scholar 

  • Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X (2008) The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 13:3273–3287

    Article  CAS  PubMed  Google Scholar 

  • Chernicky C, Yi L, Tan H, Gan S, Ilan J (2000) Treatment of human breast cancer cells with antisense RNA to the type 1 insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 7:385–395

    Google Scholar 

  • Clark MA, Fisher C, Judson IM, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701–711

    Article  CAS  PubMed  Google Scholar 

  • Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A (2007) Ionising radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26:2423–2434

    Article  CAS  PubMed  Google Scholar 

  • Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD et al (2005) Delayed activation of the insulin-like growth factor-1 receptro/Src/MAPL/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 280:14212–14221

    Article  CAS  PubMed  Google Scholar 

  • Djavan B, Waldert M, Seitz C, Marberger M (2001) Insulin-like growth factors and prostate cancer. World J Urol 19:225–233

    Article  CAS  PubMed  Google Scholar 

  • Druckman R, Rohr U (2002) IGF-1 in gynaecology and obstetrics. Maturitas 41:S65–S83

    Article  Google Scholar 

  • Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager M, Larsson O (2002) Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Opthalmol Vis Sci 43:1–8

    Google Scholar 

  • Featherstone C, Jackson SP (1999) Ku, a DNA repair protein with multiple cellular functions? Mutat Res 434:3–15

    CAS  PubMed  Google Scholar 

  • Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL et al (2007) American Cancer Society, Atlanta, GA

  • Ge J, Chen Z, Wu S, Chen J, Li X, Li J et al (2009) Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80:148–158

    Google Scholar 

  • Gil-Ad I, Shtaif B, Luria D, Karp L, Fridman Y, Weizman A (1999) Insulin like growth factor 1 (IGF-1R) antagonises apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture. Growth Horm IGF Res 9:458–464

    Article  CAS  PubMed  Google Scholar 

  • Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131:3109S–3120S

    CAS  PubMed  Google Scholar 

  • Girnita L, Girnita A, Prete F, Bartolazzi A, Larrson O, Axelson M (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64:236–242

    Article  CAS  PubMed  Google Scholar 

  • Gooch JL, Van Den Berg CL, Yee D (1999) Insulin-like growth factor 1 (IGF-1) rescues breast cancer cells from chemotherapy-induced cell death—proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56:1–10

    Article  CAS  PubMed  Google Scholar 

  • Hakam A, Yeatman T, Lu L, Mora L, Marcet G, Nicosia S et al (1999) Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30:1128–1133

    Article  CAS  PubMed  Google Scholar 

  • Haluska P, Shaw H, Batzel GN, Molife LR, Adjei AA, Yap TA et al (2007) Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. ASCO Meet Abstr 25:3586

    Google Scholar 

  • Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198–1207

    Article  CAS  PubMed  Google Scholar 

  • Hartog H, Wesseling J, Boezen HM, van der Graaf WT (2007) The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 43:1895–1904

    Article  CAS  PubMed  Google Scholar 

  • Harzstark AL, Ryan C, Diamond M, Jones J, Zavodovskaya M, Maddux B et al (2007) A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. J Clin Oncol 25:15500

    Google Scholar 

  • Hewish M, Chau I, Cunningham D (2009) Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 4:54–72

    Article  CAS  PubMed  Google Scholar 

  • Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL et al (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. ASCO Meet Abstr 26:3520

    Google Scholar 

  • Higano CS, Yu EY, Whiting SH, Gordon MS, LoRusso P, Fox F et al (2007) A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. ASCO Meet Abstr 25:3505

    Google Scholar 

  • Hochberg Z (2002) Mechanisms of steroid impairment of growth. Horm Res 58:33–38

    Article  CAS  PubMed  Google Scholar 

  • Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161–170

    Article  CAS  PubMed  Google Scholar 

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics. CA Cancer J Clin 56:106–130

    Article  PubMed  Google Scholar 

  • Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM (1999) Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-1 receptor. Oncogene 18:6071–6077

    Article  CAS  PubMed  Google Scholar 

  • Karp DD, Paz-Ares LG, Blakely LJ, Kreisman H, Eisenberg PD, Cohen RB et al (2007) Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Meet Abstr 25:7506

    Google Scholar 

  • Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F et al (2009) Phase II study of the efficacy of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. J Clin Oncol 27:2516–2522

    Article  CAS  PubMed  Google Scholar 

  • Kasper B, Gil T, D’Hondt V, Gebhart M, Awada A (2007) Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 62:9–15

    Article  PubMed  Google Scholar 

  • Korc M (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7:25–41

    CAS  PubMed  Google Scholar 

  • Kuhn C, Hurwitz SA, Kumar MG, Cotton J, Spandau DF (1999) Activation of the insulin like growth factor-1 receptor promotes the survival o human keratinocytes following ultraviolet B irradiation. Int J Cancer 80:431–438

    Article  CAS  PubMed  Google Scholar 

  • Lacy M, Alsina M, Melvin CL, Roberts L, Yin D, Petersen A et al (2006) Phase 1 first-in-human dose escalation study of cp-751,871, a specific monoclonal antibody against the insulin like growth factor 1 receptor. J Clin Oncol 24:7609

    Google Scholar 

  • Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 Receptor monoclonal antibody CP-751, 871 in patients with multiple myeloma. J Clin Oncol 26:3196–3203

    Article  CAS  PubMed  Google Scholar 

  • Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L et al (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68:7966–7974

    Article  CAS  PubMed  Google Scholar 

  • Larrson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor 1 receptor signaling in cancer. Br J Cancer 92:2097–2101

    Article  Google Scholar 

  • Lee C, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik I et al (1996) Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 56:3038–3041

    CAS  PubMed  Google Scholar 

  • Lee JY, Han CY, Yang JW, Smith C, Kim SK, Lee EY et al (2007) Induction of glutathione transferase in insulin-like growth factor 1 receptor—overexpressed hepatoma cells. Mol Pharmacol 72:1082–1093

    Article  CAS  PubMed  Google Scholar 

  • Liu X, Turbyville T, Fritz A, Whitesell L (1998a) Inhibition of insulin-like growth factor 1 receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 58:5432–5438

    CAS  PubMed  Google Scholar 

  • Liu Y, Lehar S, Corvi C, Payne G, O’Connor R (1998b) Expression of the insulin like growth factor 1 receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res 58:570–576

    CAS  PubMed  Google Scholar 

  • Lloret M, Lara PC, Bordon E, Pinar B, Rev A, Falcon O et al (2007) IGF-1R expression in localised cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol 106:8–11

    Article  CAS  PubMed  Google Scholar 

  • Lopez T, Hanahan D (2002) Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1:339–353

    Article  CAS  PubMed  Google Scholar 

  • Macaulay VM (2004) The IGF receptor as anticancer treatment target. Novartis Found Symp 262:235–243 (discussion 243–246)

    Article  CAS  PubMed  Google Scholar 

  • Maloney E, McLaughlin J, Dagdigian N, Garrett L, Connors K, Zhou XH et al (2003) An anti-insulin-like growth factor 1 receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073–5083

    CAS  PubMed  Google Scholar 

  • Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E et al (2006) A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444:1038–1043

    Article  CAS  PubMed  Google Scholar 

  • Peters JM, Tsark EC, Wiley LM (1996) Radiosensitive target in the mouse embryo chimera assay: implications that the target involves autocrine growth factor function. Radiat Res 175:722–729

    Article  Google Scholar 

  • Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224–1228

    Article  CAS  PubMed  Google Scholar 

  • Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R (1994a) Growth inhibition of human melanoma cells in nude mice by antisense strategies to type 1 insulin-like growth factor receptor. Cancer Res 54:4848–4850

    CAS  PubMed  Google Scholar 

  • Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R et al (1994b) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1R) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218–2222

    CAS  PubMed  Google Scholar 

  • Riedemann J, Sohail M, Macaulay VM, Riedemann J, Sohail M, Macaulay VM (2007) Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. Biochem Biophys Res Commun 355:700–706

    Article  CAS  PubMed  Google Scholar 

  • Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM, Rochester MA et al (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 12:90–100

    Article  CAS  PubMed  Google Scholar 

  • Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dias C (2007) A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. ASCO Meet Abstr 25:3590

    Google Scholar 

  • Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8:197–209

    Article  CAS  PubMed  Google Scholar 

  • Salisbury AJ, Macaulay VM (2003) Development of molecular agents for IGF receptor targeting. Horm Metab Res 35:843–849

    Article  CAS  PubMed  Google Scholar 

  • Samani A, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47

    Article  CAS  PubMed  Google Scholar 

  • Sarantopoulos J, Mita AC, Mulay M, Romero O, Lu J, Capilla F et al (2008) A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). ASCO Meet Abstr 26:3583

    Google Scholar 

  • Scharf J, Dombrowski F, Ramadori G (2001) The IGF axis and hepatocarcinogenesis. J Clin Pathol 54:138–144

    Article  CAS  Google Scholar 

  • Scotlandi K (2006) Targeted therapies in Ewing’s sarcoma. Adv Exp Med Biol 587:13–22

    CAS  PubMed  Google Scholar 

  • Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S et al (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65:3868–3876

    Article  CAS  PubMed  Google Scholar 

  • Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90:11217–11221

    Article  CAS  PubMed  Google Scholar 

  • Surmacz E (2000) Function of the IGF-1 Receptor in breast cancer. J Mammary Gland Biol Neoplasia 5:95–105

    Article  CAS  PubMed  Google Scholar 

  • Surmacz E (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor 1 receptor. Oncogene 22:6589–6597

    Article  CAS  PubMed  Google Scholar 

  • Tanaka S, Arii S (2009) Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100:1–8

    Article  CAS  PubMed  Google Scholar 

  • Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L et al (2007) A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. ASCO Meet Abstr 25:3002

    Google Scholar 

  • Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C et al (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients (pts) with advanced solid tumor. ASCO Meet Abstr 26:3582

    Google Scholar 

  • Traxler P (2003) Tyrosine kinases as targets in cancer therapy—successes and failures. Oncol Res 7:215–234

    CAS  Google Scholar 

  • Turner B, Haffty B, Narayanan L, Yuan J, Havre P, Gumbs A et al (1997) Insulin-like growth factor-1 receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:3079–3083

    CAS  PubMed  Google Scholar 

  • Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O (2004) The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23:7854–7862

    Article  CAS  PubMed  Google Scholar 

  • Von Mehren M (2003) New therapeutic strategies for soft tissue sarcomas. Curr Opin Oncol 4:441–451

    Google Scholar 

  • Werner H, Le Roith D (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Proc Natl Acad Sci USA 93:8318–8323

    Article  Google Scholar 

  • Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials—early lessons. J Mammary Gland Biol Neoplasia 13:471–483

    Article  PubMed  Google Scholar 

  • Wunder J, Nielsen T, Maki R, O’Sullivan B, Alman B (2007) Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8:513–524

    Article  PubMed  Google Scholar 

  • Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O (1999) Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 59:3588–3591

    Google Scholar 

  • Yakar S, LeRoith D, Brodt P (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407–420

    Article  CAS  PubMed  Google Scholar 

  • Yang JL, Crowe PJ (2007) Targeted therapies in adult soft tissue sarcomas. J Surg Oncol 95:183–184

    Article  CAS  PubMed  Google Scholar 

  • Zaidi SH, Huddart RA, Harrington KJ (2009) Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 6:103–134

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

I confirm that all authors do not have any conflict of interest.

Author information

Authors and Affiliations

  1. Surgical Oncology Research Group, Oncology Research Centre, Faculty of Medicine, Prince of Wales Hospital, University of New South Wales, Level 2 Clinical Sciences Building, Randwick, Sydney, NSW, 2031, Australia

    Alyse Hopkins & Jia-Lin Yang

  2. Department of Surgery, Faculty of Medicine, Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia

    Philip J. Crowe

Authors
  1. Alyse Hopkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip J. Crowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jia-Lin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jia-Lin Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hopkins, A., Crowe, P.J. & Yang, JL. Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 136, 639–650 (2010). https://doi.org/10.1007/s00432-010-0792-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-010-0792-0

Keywords

Search

Navigation